6318-20-3

Usage

Uses

Used in Pharmaceutical Industry:
4-Acetoxy-3,5-dimethoxybenzoic acid is used as a pain reliever and fever reducer for its ability to inhibit the production of prostaglandins, hormone-like substances that contribute to inflammation and pain in the body. It is commonly found in over-the-counter medications such as aspirin.
Used in Cardiovascular Applications:
In the cardiovascular field, 4-Acetoxy-3,5-dimethoxybenzoic acid is used as an antiplatelet agent, preventing blood clot formation and reducing the risk of heart attacks and strokes. Its antiplatelet effects are attributed to the inhibition of cyclooxygenase-1 (COX-1) enzyme, which reduces the synthesis of thromboxane A2, a potent platelet aggregator.
Used in Anti-inflammatory Applications:
4-Acetoxy-3,5-dimethoxybenzoic acid is used as an anti-inflammatory agent, reducing inflammation by inhibiting the production of prostaglandins. Its anti-inflammatory properties make it useful in the treatment of conditions such as arthritis, where inflammation can cause pain and stiffness in the joints.
Used in Cancer Therapy:
4-Acetoxy-3,5-dimethoxybenzoic acid may have potential applications in the treatment of certain types of cancers. Its ability to inhibit COX enzymes and reduce inflammation may contribute to the prevention and treatment of cancer by reducing cell proliferation and promoting apoptosis in cancer cells.
Used in Neurodegenerative Disease Treatment:
4-Acetoxy-3,5-dimethoxybenzoic acid may also have potential applications in the treatment of neurodegenerative diseases, such as Alzheimer's disease. Its anti-inflammatory and antioxidant properties may help protect neurons from damage and slow down the progression of these diseases.

InChI:InChI=1/C11H12O6/c1-6(12)17-10-8(15-2)4-7(11(13)14)5-9(10)16-3/h4-5H,1-3H3,(H,13,14)

Upstream product

• 110-86-1 pyridine 
• 643-84-5 malvidin chloride 
• 75-36-5 acetyl chloride 
• 530-57-4 3,5-dimethoxy-4-hydroxybenzoic acid 
• 127-09-3 sodium acetate 
• 108-24-7 acetic anhydride 
• 118-41-2 Eudesmic acid 
• 90985-68-5 3-(4-acetoxy-3,5-dimethoxyphenyl)prop-2-enoic acid 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 572-09-8 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 

Downstream Products

• 40638-65-1 4-acetoxy-3,5-dimethoxy-2-nitrobenzoic acid 
• 1315318-70-7 3,5-dimethoxy-4-(2-amino-3-prop-2-ynylsulfanylpropionyl)benzoic acid 4-guanidinobutyl ester 

Relevant academic research and scientific papers

Leonurine derivative and application thereof in preparing medicine for preventing or treating ischemic cerebrovascular diseases

The invention provides a leonurine derivative and application of the leonurine derivative in preparation of a medicine for preventing or treating ischemic cerebrovascular diseases. The leonurine derivative has a structure as shown in a general formula (I), wherein X is selected from O or NH; Y is selected from any one of natural amino acid, substituted amino acid or amino alcohol; Z is selected from H, proline and any substituted proline. Pharmacological experiments prove that the leonurine derivative provided by the invention has the effects of neuroprotection, cerebral infarction area reduction and animal neurobehavioral scoring, and is good in safety, so that the leonurine derivative has important significance for developing novel medicines for preventing or treating ischemic cerebrovascular diseases.

Novel Stachydrine-Leonurine Conjugate SL06 as a Potent Neuroprotective Agent for Cerebral Ischemic Stroke

As major active ingredients of the traditional Chinese medicine motherwort, stachydrine and leonurine were found to have protective effects against cerebral ischemia. However, their bioavailability in vivo was low, and their efficacy was unsatisfactory, which limited their further application. To solve these problems, the conjugates based on the structures of stachydrine and leonurine were designed and synthesized. SL06 was found to have neuronal cell survival improvement, neuronal apoptosis restraining, activation of superoxide dismutase (SOD) activity, and inhibition of lactic dehydrogenase (LDH), reactive oxygen species (ROS), malondialdehyde (MDA) in vitro. In vivo, the infarction size was significantly reduced by SL06 in the middle cerebral artery occlusion rat model. SL06 could also activate protein kinase B (AKT)/glycogen synthase kinase 3β (GSK-3β) activity and promoted the expression of antiapoptoticprotein Bcl-2. On the other hand, the expression of the apoptosis-associated protein cleaved caspase-3 would be inhibited as well. Thus, SL06 as the neuroprotective agent has potential for the treatment of cerebral ischemic stroke.

Design and synthesis of novel SCM-198 analogs as cardioprotective agents: Structure-activity relationship studies and biological evaluations

SCM-198 (Leonurine) has attracted great attention due to its cardioprotective effects in myocardial infarction (MI). However, no systematic modifications and structure-activity relationship (SAR) studies could be traced so far. In this study, 35 analogs of SCM-198 were designed, synthesized and their cardioprotective effects were evaluated. The cell viability assay on cardiomyocyte cell line H9c2 challenged with H2O2 showed that several analogs exhibited more potent cytoprotective effects than SCM-198 at 1 μM and 10 μM concentrations. LDH release level in cells treated with 1 μM 14o was comparable with cells treated with 10 μM SCM-198. Results of Bcl-2 expression and caspase-3 activation accordingly indicated higher protective activity of 14o than SCM-198. Moreover, in a mouse model of MI, the mice pretreated with 14o had much lower infarct size compared with that of SCM-198. The mechanism study suggested that 14o improved cardiac morphology and reduced apoptosis of cardiomyocytes in the border zone of infarction, as proved by H&E and TUNEL staining.

Menthyl syringate and preparation method and application thereof

The invention discloses menthyl syringate and a preparation method and application thereof. The preparation method of menthyl syringate comprises the steps that acetyl syringic acid and L-menthol areused as raw materials to conduct esterification so as to

Synthetic method for leonurine

The invention relates to the technical field of organic chemistry, in particular to a synthetic method for leonurine. Gamma-butyrolactone is used as a starting material to be subjected to ammonolysis to obtain gamma-hydroxybutyric acid amide; the gamma-hydroxybutyric acid amide and acetyl syringic acid are subjected to a condensation reaction; a dehydration reaction and a reduction reaction are carried out to obtain leonurus amine; and the leonurus amine and S-methyl isothiourea sulfate are subjected to a reaction to obtain the leonurine. The target product leonurine is synthetized from the cheap industrial raw materials of the gamma-butyrolactone and the syringic acid used as the starting materials through reactions of ammonolysis, esterification, dehydration, reduction and the like. The reaction conditions are mild and easy to control; the yield is up to 65%; the product purity is 98% or above; and the synthetic method for leonutine provides the production with an excellent synthetic route and is suitable for large-scale production.

Preparation method of leonurine and aspirin conjugate

The invention belongs to the field of medicinal chemistry, and relates to a synthesizing method of leonurine and aspirin conjugate. The method comprises the steps that syringic acid, S-methylisothiourea and aspirin serve as starting materials, reactions o

Leonurine metabolite and preparation method thereof

The invention belongs to the field of medicine synthesis, and particularly relates to a leonurine main metabolite and a preparation method thereof. The main metabolite which has a structure shown in the formula (I) (please see the formula in the descripti

1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity formula (I) to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives

The present invention relates to 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives having pharmacological activity to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and/or prophylaxis of a cognitive disorder.

Factors influencing the antifolate activity of synthetic tea-derived catechins

Novel tea catechin derivatives have been synthesized, and a structure-activity study, related to the capacity of these and other polyphenols to bind dihydrofolate reductase (DHFR), has been performed. The data showed an effective binding between all molecules and the free enzyme, and the dissociation constants of the synthetic compounds and of the natural analogues were on the same order. Polyphenols with a catechin configuration were better DHFR inhibitors than those with an epicatechin configuration. Antiproliferative activity was also studied in cultured tumour cells, and the data showed that the activity of the novel derivatives was higher in catechin isomers. Derivatives with a hydroxyl group para on the ester-bonded gallate moiety presented a high in vitro binding to DHFR, but exhibited transport problems in cell culture due to ionization at physiologic pHs. The impact of the binding of catechins to serum albumin on their biological activity was also evaluated. The information provided in this study could be important for the design of novel medicinal active compounds derived from tea catechins. The data suggest that changes in their structure to avoid serum albumin interactions and to facilitate plasmatic membrane transport are essential for the intracellular functions of catechins.